logo

Biondvax Pharmaceuticals Ltd. (BVXV)



Trade BVXV now with
  Date
  Headline
1/29/2021 8:05:32 AM BiondVax Announces Pricing Of $12.1 Mln Follow-on Underwritten Offering Of American Depositary Shares
1/28/2021 7:50:31 PM BiondVax Announces Launch Of Proposed Underwritten Follow-on Offering Of ADSs
1/21/2021 7:17:26 AM BiondVax Appoints Amir Reichman As CEO, Effective March 2, 2021
10/23/2020 10:41:01 AM BiondVax Announces Results From Phase 3 Trial Of The M-001 Universal Influenza Vaccine Candidate
10/2/2020 6:01:52 AM BiondVax Announces At-The-Market Equity Offering Program
7/1/2020 6:03:06 AM BiondVax: Last Of 12,400 Participants Completes Final Visit In M-001 Universal Flu Vaccine Pivotal Phase 3 Trial
6/12/2020 8:07:37 AM BiondVax Pharma FY Loss Per Share NIS 0.33 Vs Loss NIS 0.34 Last Year
6/10/2020 7:07:18 AM BiondVax Pharma Reports Completion Of CSR Of Phase 2 Clinical Trial Of M-001 Universal Influenza Vaccine Candidate
5/20/2020 6:35:02 AM BiondVax Announces Receipt Of Proceeds Of $4.2 Mln Since January 1, 2020 Through Exercises Of BiondVax Warrants
3/19/2020 7:19:48 AM BiondVax's CEO Says Coronavirus Pandemic Has Not Significantly Impacted Phase 3 Clinical Trial
11/18/2019 7:21:18 AM BiondVax Pharma Complets Enrollment Of 12,463 Participants Complete In Pivotal Phase 3 Universal Flu Vaccine Trial
8/28/2019 7:49:29 AM BiondVax Pharma Names Mark Germain Chairman, Effective Sept 30
7/8/2019 5:48:48 AM BiondVax Enrolls First Participants In Second Cohort Of Pivotal, Clinical Efficacy, Phase 3 Trial Of M-001
6/18/2019 6:36:26 AM BiondVax Pharma Says Patent Covering Manufacturing Process Of M-001 Universal Flu Vaccine Allowed In USA And Japan